Lisata Therapeutics

Cell therapy

LSTA · Nasdaq · United States

Share price · LSTA

$0.98-0.17 (-14.77%) 3M

close as of 2026-11-18 · 24h delayed · vol 222K (1.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LSTA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+17.6%

    Nothing announced by LSTA that day or the session before.

  2. 21 Aug 2026+38.4%
  3. 28 Jul 2026-19.4%

    Nothing announced by LSTA that day or the session before.

  4. 27 Jul 2026-13.8%
  5. 24 Jul 2026-21.2%
  6. 21 Jul 2026-36.5%

    Nothing announced by LSTA that day or the session before.

  7. 13 Jul 2026+13.1%

    Nothing announced by LSTA that day or the session before.

  8. 1 Jun 2026+10.2%
  9. 21 Apr 2026+12.4%

    Nothing announced by LSTA that day or the session before.

  10. 20 Apr 2026-12.4%

    Nothing announced by LSTA that day or the session before.

Share of unusual movement by asset

For each asset, the share of LSTA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
certepetide
events and moves
7shown from 8 days
MAR001
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—9%
Other company news (earnings, financing, releases naming no asset)—49%
Sessions with no dated event—42%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
Alpha-v integrins and neuropilin-1 (CendR tumour-penetration pathway)Peptide
Pancreatic Cancer
Phase 2
ANGPTL4Monoclonal antibody
Cardiovascular Disease / Dyslipidemia
Hypertriglyceridemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
MAR001Phase 2Hypertriglyceridemia
Est. primary completion 2027-11 · NCT07028749 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 November 2026Topline resultMAR001TYDAL-TIMI 78 Part A: MAR001 lowers fasting triglycerides at week 12 (AHA 2026, NEJM)
TIMI Study Group / Marea Therapeutics · Source ↗
26 June 2025Topline resultcertepetideASCEND Phase 2b Cohort B preliminary results
22 January 2025Topline resultcertepetidePreliminary Cohort A data from Phase 2 ASCEND trial

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$5.2M$283M$6.8M-$13M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$0.6M$10M$2.9M-$2.6M operating cash flowreport ↗
2026-Q1$0$1.2M$13M$4.5M-$3.1M operating cash flowreport ↗
2025-Q3$0$2.0M$19M$4.3M-$3.3M operating cash flowreport ↗
2025-Q2$0.1M$2.3M$17M+ $0.4M short-term inv.$4.7M-$4.0M operating cash flowreport ↗
2025-Q1$0$2.6M$20M+ $2.8M short-term inv.$4.7M-$5.4M operating cash flowreport ↗
2024-Q3$0$2.5M$20M+ $11M short-term inv.$4.9M-$2.5M operating cash flowreport ↗
2024-Q2$0$2.6M$28M+ $5.5M short-term inv.$5.0M-$5.3M operating cash flowreport ↗
2024-Q1$0$3.2M$22M+ $17M short-term inv.$5.4M-$7.0M operating cash flowreport ↗
2023-Q3$0$3.4M$32M+ $19M short-term inv.$5.3M-$3.6M operating cash flowreport ↗
2023-Q2$0$3.2M$24M+ $30M short-term inv.$4.0M-$4.2M operating cash flowreport ↗
2023-Q1$0$3.2M$28M+ $27M short-term inv.$6.2M-$8.2M operating cash flowreport ↗
2022-Q3$0$3.4M$31M+ $36M short-term inv.$37M-$4.0M operating cash flowreport ↗
2022-Q2—$3.2M$33M+ $36M short-term inv.$6.6M-$5.1M operating cash flowreport ↗
2022-Q1—$3.3M$13M+ $74M short-term inv.$4.2M-$5.6M operating cash flowreport ↗
2021-Q3—$4.1M$13M+ $84M short-term inv.$6.9M-$5.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.2M$8.0M$16M$4.2M-$16M operating cash flowreport ↗

Lisata Therapeutics reported revenue of $0.17M for fiscal 2025, down 83.0% YoY, with R&D spend of $7.95M, down 29.8% YoY. The company held cash and equivalents of $15.96M and recorded a net loss of $16.59M, with quarterly net burn of $16.59M as reported.

The company’s narrative centers on its investigational product certepetide, including preliminary ASCEND trial data in metastatic pancreatic cancer, a completed BOLSTER trial in cholangiocarcinoma, and ongoing investigator-initiated trials. It also disclosed a proposed acquisition by Kuva Labs Inc. under a merger agreement dated March 6, 2026, with a tender offer of $5.00 per share plus a contingent value right of $1.00, expected to close in the second quarter of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.0M$11M$16M+ $9.4M short-term inv.$5.0M-$19M operating cash flowreport ↗
2023-FY$0$13M$23M+ $22M short-term inv.$5.2M-$20M operating cash flowreport ↗
2022-FY$0$13M$32M+ $33M short-term inv.$14M-$21M operating cash flowreport ↗
2021-FY—$18M$25M+ $67M short-term inv.$6.9M-$22M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-01-09AZAB MOHAMMAD · directorAward / grant30,456——Form 4
2026-01-09BROWN GREGORY B · directorAward / grant30,456——Form 4
2026-01-09Flowers Cynthia Louise · directorAward / grant30,456——Form 4
2026-01-09HENSON HEIDI · directorAward / grant30,456——Form 4
2026-01-09KLOSK STEVEN M · directorAward / grant30,456——Form 4
2026-01-09Buck Kristen K · EVP, R&D and CMOAward / grant25,000——Form 4
2026-01-09Imam Tariq · SVP, Bus Dev, General CounselAward / grant15,000——Form 4
2026-01-09Nisco James · SVP, Fin/Treas, Chief Actg OffAward / grant15,000——Form 4